Hamlin Capital Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
Sell
-2,314,277
Closed -$71.7M 42
2020
Q1
$71.7M Buy
2,314,277
+112,243
+5% +$3.82M 4.29% 3
2019
Q4
$81.9M Sell
2,202,034
-4,961
-0.2% -$177K 3.41% 8
2019
Q3
$75.2M Sell
2,206,995
-129,007
-6% -$4.69M 3.38% 11
2019
Q2
$96M Sell
2,336,002
-29,537
-1% -$1.17M 4.12% 3
2019
Q1
$95.3M Sell
2,365,539
-84,039
-3% -$3.37M 4.25% 5
2018
Q4
$101M Sell
2,449,578
-342,792
-12% -$14.2M 4.72% 2
2018
Q3
$117M Sell
2,792,370
-100,286
-3% -$3.86M 4.58% 1
2018
Q2
$99.6M Sell
2,892,656
-86,586
-3% -$2.96M 4.05% 4
2018
Q1
$100M Buy
2,979,242
+9,818
+0.3% +$338K 3.88% 6
2017
Q4
$102M Sell
2,969,424
-67,861
-2% -$2.31M 3.92% 5
2017
Q3
$103M Sell
3,037,285
-12,510
-0.4% -$402K 4.17% 6
2017
Q2
$97.2M Buy
3,049,795
+48,786
+2% +$1.54M 4.06% 3
2017
Q1
$97.4M Buy
3,001,009
+838,050
+39% +$26.4M 4.11% 1
2016
Q4
$66.7M Buy
2,162,959
+459,632
+27% +$14M 2.98% 12
2016
Q3
$54.7M Sell
1,703,327
-39,701
-2% -$1.33M 2.53% 24
2016
Q2
$58.2M Buy
1,743,028
+47,117
+3% +$1.5M 2.82% 20
2016
Q1
$47.7M Buy
+1,695,911
New +$48.4M 2.41% 29

Other funds holding PFE

Hamlin Capital Management's PFE Position: Q2 2020 in Review

Hamlin Capital Management sold out of Pfizer (PFE) in Q2 2020, closing a stake of 2,314,277 shares — an estimated $71.7M sold.

Hamlin Capital Management first reported a position in PFE in Q1 2016 and held it in 17 quarters. The position peaked at $117M in Q3 2018. 2,441 funds tracked by Wall St. Rank hold PFE as of Q2 2020.

  • Hamlin Capital Management reported no remaining Pfizer position as of Q2 2020 after selling out during the quarter.
  • Hamlin Capital Management sold 2,314,277 Pfizer shares in Q2 2020, an estimated $71.7M.
  • Hamlin Capital Management first reported a position in Pfizer in Q1 2016 and held it in 17 quarters.
  • Hamlin Capital Management's Pfizer position peaked at $117M in Q3 2018.
  • 2,441 funds tracked by Wall St. Rank held Pfizer as of Q2 2020.

Based on Hamlin Capital Management's 13F filing for Q2 2020, filed 15 Jul 2020.